Vassiliki Economides, newly appointed Chief Financial Officer of Adial Pharmaceuticals, Inc., filed an initial statement of beneficial ownership on October 30, 2026, reporting a stock option position as of the event date of October 28, 2026.

Key Highlights

  • Reporting person: Vassiliki Economides, identified as Chief Financial Officer of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL).
  • Event date: The date of event requiring the statement is October 28, 2026.
  • Derivative security: A stock option (right to buy) covering 307,814 shares of Common Stock, held directly.
  • Exercise price: $5.76 per share, with an expiration date of August 19, 2036.
  • Vesting schedule: According to the filing, 25% vests on the first anniversary of the grant date (August 19, 2026), with the remaining shares vesting in 36 equal monthly installments thereafter, subject to continuous service.
  • Non-derivative holdings: No non-derivative securities were reported in Table I of the filing.

Adial Pharmaceuticals CFO Economides Discloses Initial Option Holdings

Vassiliki Economides filed a Form 3 - Initial Statement of Beneficial Ownership of Securities with the U.S. Securities and Exchange Commission on October 30, 2026, in connection with her role as Chief Financial Officer of Adial Pharmaceuticals, Inc. The issuer is identified in the filing as ADIAL PHARMACEUTICALS, INC., trading under the ticker ADIL on NASDAQ. The date of the event requiring the statement is listed as October 28, 2026.

According to the filing, Economides holds one derivative security: a stock option (right to buy) covering 307,814 shares of Common Stock. The option carries an exercise price of $5.76 per share and an expiration date of August 19, 2036. The ownership form is listed as direct. The filing notes, in explanation of the option, that "the option shall vest as to 25% on the first anniversary of the grant date (August 19, 2026), with the remaining shares vesting in a series of 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through the applicable vesting date."

Table I of the filing, covering non-derivative securities beneficially owned, contains no entries, indicating that no shares of common stock or other non-derivative securities were reported at the time of the initial filing. The form was filed by one reporting person, and the signature was provided by Matthew Davidson as Attorney-in-Fact, with an attached Exhibit 24 Power of Attorney, as noted in the filing's remarks.

What Was Disclosed

Vassiliki Economides, CFO of Adial Pharmaceuticals, filed an initial beneficial ownership statement disclosing a stock option to purchase 307,814 shares of Common Stock at $5.76 per share, expiring August 19, 2036, with a four-year vesting schedule. No non-derivative securities were reported.